Journal article
Abstract 10249: Association of Eligibility for a Sodium-Glucose Co-Transporter 2 Inhibitor and Cardiovascular Outcomes in Patients with Atrial Fibrillation
Abstract
Introduction: Heart failure (HF) is the leading cause of death in patients with atrial fibrillation (AF). Although sodium-glucose co-transporter 2 inhibitors (SGLT2i) reduce HF in a broad range of populations, they have not been studied specifically in patients with AF. Objective: We aimed to determine the proportion of AF patients who are eligible for an SGLT2i based on co-morbidities, and compare their risk of cardiovascular outcomes to …
Authors
Oraii A; Healey JS; Fonguh S; Wang J; Pandey AK; Conen D; Connolly SJ; McIntyre WF
Journal
Circulation, Vol. 144, No. Suppl_1, pp. a10249–a10249
Publisher
Wolters Kluwer
Publication Date
November 16, 2021
DOI
10.1161/circ.144.suppl_1.10249
ISSN
0009-7322